Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach
- Author(s)
- Sorich, MJ; Manning-Bennett, AT; Li, LX; Shahnam, A; Kichenadasse, G; Karapetis, CS; Abuhelwa, AY; McKinnon, RA; Rowland, A; Hopkins, AM;
- Details
- Publication Year 2025-03,Volume 20,Issue #2,Page 361-369
- Journal Title
- Targeted Oncology
- Publication Type
- Research article
- Abstract
- Tumour mutational burden (TMB) is an established biomarker for patients treated with immune checkpoint inhibitors (ICIs). The optimal TMB cut-off is uncertain. It is also uncertain whether there is a sharp TMB threshold or a more graduated change in clinical outcomes as TMB increases.
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1007/s11523-024-01124-2
- Open Access at Publisher's Site
https://doi.org/10.1007/s11523-024-01124-2- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-01-16 04:34:22
Last Modified: 2026-01-16 04:35:16